BioSpace News Archive

Deals

Can-Fite’s Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

As a result of the merger, Can-Fite’s ownership of OphthaliX, immediately post-merger, became approximately 8% of the outstanding shares.

November 17, 2017

·

5 min read

Drug Development

Patients Who Used Optune More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial

This is a median survival of 24.9 months from randomization and a five-year survival of 29.3 percent.

November 17, 2017

·

8 min read

Ncardia Announces Completion of 10.5M Euros Investment Round

The round was led by Épimède, a Belgium venture capital firm.

November 17, 2017

·

2 min read

Deals

Roche Scoops Up Bay Area’s Viewics Amid Diagnostic Data Push

Under the deal, Roche is acquiring all shares of the company.

November 17, 2017

·

4 min read

BioMidwest

Indiana University School of Medicine Researchers Identify First Brain Training Exercise Positively Linked to Dementia Prevention

The cognitive training, called speed of processing, showed benefits up to 10 years after study participants underwent the mental exercise program, said Frederick W. Unverzagt, PhD, professor of psychiatry at Indiana University School of Medicine.

November 17, 2017

·

3 min read

OBN Celebrates Successful Inaugural BioSeed Conference Supporting Innovative Life Sciences Companies’ Accessing Seed Funding

OBN (UK) Ltd, the membership organisation that supports the life sciences industry, is delighted to announce the success of their new event BioSeed which was held on 14th November at EY’s London offices.

November 17, 2017

·

1 min read

Biotech Beach

CytRx Corporation Regains Nasdaq Listing Compliance

Separately, CytRx has engaged the services of a third party firm to conduct an in-depth investigation to determine the extent of short-selling in the Company’s common stock.

November 17, 2017

·

3 min read

Business

Vilacto Bio Inc. Retains Established Independent Investor Relations Firm, The Equity Group Inc.

Vilacto Bio selected The Equity Group due to its 43-year track record of delivering specialized, comprehensive IR programs for small- and mid-sized public companies.

November 17, 2017

·

2 min read

Business

International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017

Combined operating income for the nine months ended September 30, 2017 from our two wholly owned revenue-generating subsidiaries was $1.3 million, an increase of 30% compared to $1.0 million in the same period in 2016.

November 17, 2017

·

7 min read

Business

ViroMed Builds Team of Experts to Direct Global Drug Development and Commercialization Efforts

ViroMed announced on November 7th that it has built a global team of experts to add momentum to the global development and commercialization of VM202 by recruiting Dr. William Schmidt, Dr. Cathryn Carroll, and Dr. Marie-Laure Nevoret.

November 17, 2017

·

3 min read